John Q. Doyle, President and CEO of Marsh & McLennan Companies, Inc. (MRSH -1.44%), reported the sale of 16,656 shares of common stock on Sept. 2, 2026. SEC Form 4 filing
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $3.1 million |
| Shares sold (directly held) | 16,656 |
| Post-transaction shares (directly held) | 116,811 |
| Post-transaction value | $21.94 million |
Transaction value based on SEC Form 4 weighted average sale price ($188.51); post-transaction value based on Sept. 2, 2026 market close ($187.84).
Key questions
- What role did the Rule 10b5-1 plan play in this transaction?
John Q. Doyle utilized a pre-established Rule 10b5-1 trading plan, which provides a systematic framework for insiders to manage equity positions without the influence of subsequent material information. - When were the underlying derivative securities granted?
The 16,656 options exercised by the CEO were originally granted on February 22, 2017, and reached full vesting in four annual installments by February 2021. - How has the stock performed relative to this transaction price?
The weighted average sale price of $188.51 occurred as the company shares recorded a -9% one-year return as of the Sept. 2, 2026 market close. - What is the scale of the CEO’s remaining direct equity position?
Following this transaction, the CEO retains ~117,000 shares of common stock held directly, representing a total market value of $21.94 million as of the latest valuation date.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-02) | $187.84 |
| Market Capitalization | $90.4 billion |
| Revenue (TTM) | $27.9 billion |
| Net Income (TTM) | $4.0 billion |
Company Snapshot
- Marsh & McLennan Companies operates as a leading professional services firm providing comprehensive risk management, insurance brokerage, and consulting solutions across multiple client segments and geographies.
- The company generates revenue through insurance brokerage commissions and fees, risk consulting services, and human capital advisory solutions delivered via its portfolio of prominent brands including Marsh and McLennan.
- The firm serves multinational corporations, mid-market enterprises, and institutional clients seeking expert guidance on risk mitigation, strategic planning, and workforce optimization across diverse industries.
Marsh & McLennan Companies is a global leader in professional services with approximately 95,000 employees and a market capitalization of $90.4 billion. The firm leverages its diversified service offerings and established brand portfolio to maintain competitive advantages in the insurance brokerage and risk consulting markets. With TTM revenue of $27.9 billion and net income of $4.0 billion, the company demonstrates substantial scale and profitability within the financial services sector.
What this transaction means for investors
Retail investors should always recall that insider transactions occur for many reasons. Often, those reasons are more ordinary than what one might first expect. Insiders sometimes sell to meet tax obligations or as part of prearranged plans that have been in place for months or years. As such, investors are best served to return to a company’s fundamentals before developing a bullish or bearish thesis. With that in mind, let’s have a closer look at March & McLennan (MRSH).
For starters, let’s take a look at how MRSH stock has performed in recent years. The stock has generated a total return of 21%, equating to a compound annual growth rate (CAGR) of 3.8%. The S&P 500, meanwhile, has delivered a total return of 80% over the same period, with a CAGR of 12.5%.
Marsh & McLennan Companies
Today’s Change
(-1.44%) $-2.55
Current Price
$174.22
Key Data Points
Market Cap
Day’s Range
$173.91 – $176.18
52wk Range
$156.60 – $207.82
Volume
364.9K
Avg Vol
2.4M
Dividend Yield
2.09%
Turning to the company’s core fundamentals, MRSH displays an interesting mix of strength and weakness.
As for the positives, the company has successfully grown revenue, net income, and free cash flow over the last few years. Revenue sits at an all-time high of $28 billion. Net income has soared from $2.8 billion to $4.1 billion over the last five years. Similarly, free cash flow is near an all-time high of $4.8 billion.
However, other figures are less impressive. Operating margin reached 26.7% in 2024, but it has since retreated to 24.3%. All the while, net debt has steadily increased, and it now stands at $20.7 billion, up 74% from 2021.
To sum up, MRSH stock has underperformed the broader market. Some fundamentals, like revenue, net income, and free cash flow, show significant strength. However, others, like net debt, and operating margin, point to some vulnerabilities. Given ongoing macroeconomic headwinds, some investors may select a wait-and-see approach when it comes to MRSH stock.